SCYNEXIS (SCYX) Competitors $0.91 0.00 (-0.39%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. ACIU, TARA, DMAC, IKT, PBYI, TNGX, DERM, OGI, LYEL, and SCPHShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include AC Immune (ACIU), Protara Therapeutics (TARA), DiaMedica Therapeutics (DMAC), Inhibikase Therapeutics (IKT), Puma Biotechnology (PBYI), Tango Therapeutics (TNGX), Journey Medical (DERM), Organigram (OGI), Lyell Immunopharma (LYEL), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. AC Immune Protara Therapeutics DiaMedica Therapeutics Inhibikase Therapeutics Puma Biotechnology Tango Therapeutics Journey Medical Organigram Lyell Immunopharma scPharmaceuticals AC Immune (NASDAQ:ACIU) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership. Is ACIU or SCYX more profitable? AC Immune has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. AC Immune's return on equity of -28.26% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets AC ImmuneN/A -28.26% -18.98% SCYNEXIS -425.41%-66.21%-38.84% Do analysts recommend ACIU or SCYX? AC Immune currently has a consensus target price of $12.00, indicating a potential upside of 700.00%. Given AC Immune's stronger consensus rating and higher probable upside, equities research analysts clearly believe AC Immune is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in ACIU or SCYX? 51.4% of AC Immune shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 2.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to ACIU or SCYX? In the previous week, AC Immune had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 3 mentions for AC Immune and 2 mentions for SCYNEXIS. AC Immune's average media sentiment score of 1.81 beat SCYNEXIS's score of 0.88 indicating that AC Immune is being referred to more favorably in the media. Company Overall Sentiment AC Immune Very Positive SCYNEXIS Positive Which has better earnings and valuation, ACIU or SCYX? SCYNEXIS has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$27.31M5.52-$60.41M-$0.58-2.59SCYNEXIS$3.75M9.50$67.04M-$0.44-2.07 Which has more risk & volatility, ACIU or SCYX? AC Immune has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Does the MarketBeat Community prefer ACIU or SCYX? SCYNEXIS received 245 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 69.85% of users gave SCYNEXIS an outperform vote while only 62.65% of users gave AC Immune an outperform vote. CompanyUnderperformOutperformAC ImmuneOutperform Votes26062.65% Underperform Votes15537.35% SCYNEXISOutperform Votes50569.85% Underperform Votes21830.15% SummaryAC Immune beats SCYNEXIS on 10 of the 18 factors compared between the two stocks. Remove Ads Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.57M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-1.236.7221.6917.68Price / Sales9.50223.16371.6292.88Price / Cash0.5865.6738.1534.64Price / Book0.475.776.373.94Net Income$67.04M$142.23M$3.20B$247.45M7 Day Performance5.97%2.72%1.67%0.48%1 Month Performance-2.08%-14.04%-9.49%-7.08%1 Year Performance-35.28%-12.31%9.59%-0.35% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.3237 of 5 stars$0.91-0.4%N/A-37.7%$35.57M$3.75M-1.2360ACIUAC Immune2.505 of 5 stars$1.52-2.6%$12.00+689.5%-40.1%$152.62M$27.31M-3.30140Analyst RevisionGap DownTARAProtara Therapeutics2.0006 of 5 stars$4.14+5.9%$22.50+443.5%+46.8%$152.22MN/A-1.4730Analyst ForecastNews CoveragePositive NewsGap UpDMACDiaMedica Therapeutics1.2195 of 5 stars$3.54+2.0%$8.00+126.0%+46.9%$151.71MN/A-6.3220Short Interest ↑Gap UpIKTInhibikase Therapeutics1.4452 of 5 stars$2.00-3.4%$6.50+225.0%-13.4%$148.68M$260,000.00-0.756PBYIPuma Biotechnology3.5297 of 5 stars$2.93+3.9%$7.00+138.9%-44.7%$145.36M$230.47M6.10200TNGXTango Therapeutics1.937 of 5 stars$1.34-5.0%$12.33+820.4%-81.2%$144.87M$42.07M-1.1490Analyst ForecastAnalyst RevisionNews CoveragePositive NewsGap DownDERMJourney Medical2.3952 of 5 stars$6.21+3.0%$9.88+59.0%+53.7%$143.48M$56.13M-6.6190Short Interest ↑OGIOrganigram0.6704 of 5 stars$1.04+1.0%N/A-44.7%$131.31M$166.12M-2.74860Positive NewsLYELLyell Immunopharma3.2283 of 5 stars$0.44+1.4%$1.00+124.9%-80.9%$131.26M$61,000.00-0.56270Analyst ForecastNews CoveragePositive NewsGap DownSCPHscPharmaceuticals3.7457 of 5 stars$2.58+11.2%$14.00+442.6%-45.7%$129.73M$36.33M-1.3630Short Interest ↓Gap Down Remove Ads Related Companies and Tools Related Companies ACIU Alternatives TARA Alternatives DMAC Alternatives IKT Alternatives PBYI Alternatives TNGX Alternatives DERM Alternatives OGI Alternatives LYEL Alternatives SCPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SCYX Stock Free SCYX Stock Alerts